StageAcquired | Acquired
Missing: AviaraDX's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: AviaraDX's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
AviaraDX Frequently Asked Questions (FAQ)
When was AviaraDX founded?
AviaraDX was founded in 1996.
Where is AviaraDX's headquarters?
AviaraDX's headquarters is located at 11025 Roselle Street, San Diego.
What is AviaraDX's latest funding round?
AviaraDX's latest funding round is Acquired.
How much did AviaraDX raise?
AviaraDX raised a total of $43.8M.
Who are the investors of AviaraDX?
Investors of AviaraDX include bioMerieux, ONSET Ventures, Incubic Venture Capital, ABS Capital Partners, Industrial Technology Investment and 10 more.
Who are AviaraDX's competitors?
Competitors of AviaraDX include AltheaDx, Akonni Biosystems, Epocal, Advanced Cell Diagnostics, Clarient and 11 more.
Compare AviaraDX to Competitors
CellPoint Diagnostics is developing diagnostic, monitoring, and molecular analytical tools for cancer. Its technology captures and analyzes circulating tumor cells ("CTCs") directly from patient blood. Scientific and clinical data have demonstrated that CTCs are derived from the primary tumor, and the assessment of the number of CTCs in the blood has been shown to accurately predict survival for cancer patients.
Dilon Technologies is a medical device manufacturer that focuses on products that assist in the fight against breast cancer. The company offers a portfolio of medical devices that includes the Navigator System, a trusted brand and world-renowned surgical gamma probe for radio-guided lymphatic mapping and tumor localization, the MarginProbe, a groundbreaking technology for accurate microscopic margin assessment in breast cancer surgery, and the TrueView 100 Pro, a Specimen Radiography System (SRS) that uses advanced radiography and automated software to precisely identify tumor lesions in resected or biopsied breast tissue. The company was founded in 1999 and is based in Newport News, Virginia.
At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.
Akonni Biosystems is a molecular diagnostics (MDx) company that develops, manufactures, and markets integrated molecular diagnostic systems.
Diagnoplex is leveraging its molecular platform capabilities to develop a colorectal cancer (CRC) screening test. Diagnoplex's lead product, Colox, is a convenient and minimally-invasive blood test developed for the systematic screening of colorectal cancer. The gene signature underlying Colox has been designed to detect early and advanced disease stages with outstanding results and reliability. Colox leverages the information from nucleic acids carried by peripheral blood mononuclear cells (PBMCs). PBMCs are instrumental for tumor-host interactions, the so-called "host response", and are involved at the earliest stages of tumor formation.
Tears For Life, a medical diagnostic equipment company currently developing a non-invasive tear test kit that will be able to screen women for breast cancer using proteins found in their tears.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.